(Total Views: 736)
Posted On: 02/04/2021 4:03:01 AM
Post# of 153904
Here is a link to a CytoDyn history lesson for the new investors/people. This is a very good history lesson on Pro 140 and where it came from and all pre-Covid-19. Where we were heading prior to Covid as far as indications. Link at the bottom of post. This also shows why Nader deserves to lead this company. Without Nader. There would of been no Cytodyn and no Leronlimab. He fought to develop this MAB. We should all have an appreciation for what Nader has done and will achieve here shortly.
The best thing about this article is that it shows production capabilities. Of 150,000 and 180,000 Liter runs. We haven’t had a run this big but potential is there. 180,000/3ml vial = 60,000,000 vials. Or 30,000,000 doses. 30 million times $1,500 equals 45 billion possible revenue. That is if we can ramp up to 180,000 Liter batches at some point. Also hopefully Samsung’s new expansion isn’t already spoken for in production limits. All this time I have wondered if we needed approval from the FDA for these larger batch size runs. This article makes me assume we already have that option. Let’s hope so.
https://www.bioprocessonline.com/doc/the-peri...uster-0001
The best thing about this article is that it shows production capabilities. Of 150,000 and 180,000 Liter runs. We haven’t had a run this big but potential is there. 180,000/3ml vial = 60,000,000 vials. Or 30,000,000 doses. 30 million times $1,500 equals 45 billion possible revenue. That is if we can ramp up to 180,000 Liter batches at some point. Also hopefully Samsung’s new expansion isn’t already spoken for in production limits. All this time I have wondered if we needed approval from the FDA for these larger batch size runs. This article makes me assume we already have that option. Let’s hope so.
https://www.bioprocessonline.com/doc/the-peri...uster-0001
(9)
(0)
